» Authors » Ryan E Bash

Ryan E Bash

Explore the profile of Ryan E Bash including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 12
Citations 304
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Stackhouse C, Anderson J, Yue Z, Nguyen T, Eustace N, Langford C, et al.
JCI Insight . 2022 Jul; 7(16). PMID: 35852875
Key molecular regulators of acquired radiation resistance in recurrent glioblastoma (GBM) are largely unknown, with a dearth of accurate preclinical models. To address this, we generated 8 GBM patient-derived xenograft...
2.
Su Y, Butler M, Zhang M, Zhang W, Song H, Hwang L, et al.
Neurooncol Adv . 2020 Jul; 2(1):vdaa065. PMID: 32642716
Background: Glioblastoma-associated macrophages and microglia (GAMs) are the predominant immune cells in the tumor microenvironment. Activation of MerTK, a receptor tyrosine kinase, polarizes GAMs to an immunosuppressive phenotype, promoting tumor...
3.
McNeill R, Stroobant E, Smithberger E, Canoutas D, Butler M, Shelton A, et al.
PLoS One . 2018 Jul; 13(7):e0200014. PMID: 29975751
Background: Glioblastoma (GBM) is the most common adult primary brain tumor. Multimodal treatment is empiric and prognosis remains poor. Recurrent PIK3CA missense mutations (PIK3CAmut) in GBM are restricted to three...
4.
Wu J, Frady L, Bash R, Cohen S, Schorzman A, Su Y, et al.
Neuro Oncol . 2017 Jun; 20(1):92-102. PMID: 28605477
Background: Glioma-associated macrophages and microglia (GAMs) are components of the glioblastoma (GBM) microenvironment that express MerTK, a receptor tyrosine kinase that triggers efferocytosis and can suppress innate immune responses. The...
5.
Van Swearingen A, Sambade M, Siegel M, Sud S, McNeill R, Bevill S, et al.
Neuro Oncol . 2017 May; 19(11):1481-1493. PMID: 28486691
Background: Triple-negative breast cancer (TNBC), lacking expression of hormone and human epidermal growth factor receptor 2 receptors, is an aggressive subtype that frequently metastasizes to the brain and has no...
6.
Vitucci M, Irvin D, McNeill R, Schmid R, Simon J, Dhruv H, et al.
Neuro Oncol . 2017 Apr; 19(9):1237-1247. PMID: 28398584
Background: Gliomas are diverse neoplasms with multiple molecular subtypes. How tumor-initiating mutations relate to molecular subtypes as these tumors evolve during malignant progression remains unclear. Methods: We used genetically engineered...
7.
McNeill R, Canoutas D, Stuhlmiller T, Dhruv H, Irvin D, Bash R, et al.
Neuro Oncol . 2017 Apr; 19(11):1469-1480. PMID: 28379424
Background: Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Prognosis remains poor despite multimodal therapy. Developing alternative treatments is essential. Drugs targeting kinases within the phosphoinositide 3-kinase...
8.
Okolie O, Bago J, Schmid R, Irvin D, Bash R, Miller C, et al.
Neuro Oncol . 2016 Jun; 18(12):1622-1633. PMID: 27298311
Background: Surgical resection is a universal component of glioma therapy. Little is known about the postoperative microenvironment due to limited preclinical models. Thus, we sought to develop a glioma resection...
9.
Schmid R, Simon J, Vitucci M, McNeill R, Bash R, Werneke A, et al.
Neuro Oncol . 2016 Jan; 18(7):962-73. PMID: 26826202
Background: Glioma stem cells (GSCs) from human glioblastomas (GBMs) are resistant to radiation and chemotherapy and may drive recurrence. Treatment efficacy may depend on GSCs, expression of DNA repair enzymes...
10.
Irvin D, McNeill R, Bash R, Miller C
Brain Pathol . 2016 Jan; 27(1):36-50. PMID: 26762242
The influence of cellular origin on glioma pathogenesis remains elusive. We previously showed that mutations inactivating Rb and Pten and activating Kras transform astrocytes and induce tumorigenesis throughout the adult...